Llerena-Velastegui Jordan, Santamaria-Lasso Melisa, Mejia-Mora Melany, Granda-Munoz Andrea, Trujillo-Delgado Martin, Hurtado-Alzate Claudia, de Jesus Ana Clara Fonseca Souza, Coelho Pedro Moraes, Baldelomar-Ortiz Jurgen
Medical School, Pontifical Catholic University of Ecuador, Quito, Ecuador.
Research Center, Center for Health Research in Latin America (CISeAL), Quito, Ecuador.
J Clin Med Res. 2024 Sep;16(9):398-410. doi: 10.14740/jocmr5230. Epub 2024 Sep 4.
The management of heart failure (HF) in patients with type 2 diabetes has significantly evolved with the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors. This article aims to consolidate existing knowledge on the efficacy of these inhibitors in managing HF in this patient population. Major medical databases, including PubMed, Scopus, and Web of Science, were reviewed, prioritizing research from the last decade. The results of this review highlight the mechanisms of action of SGLT2 inhibitors, their clinical benefits, challenges in patient management, and outcomes associated with their use. These medications were found to not only improve glycemic control but also offer significant cardiovascular and renal benefits, reducing cardiovascular mortality and major adverse cardiovascular events. However, challenges and knowledge gaps persist, particularly regarding long-term effects and safety in diverse populations. The conclusions of this review underscore the importance of updating clinical guidelines to incorporate these findings and propose the need for future research to address existing gaps and optimize the use of SGLT2 inhibitors in clinical practice.
随着钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的引入，2型糖尿病患者心力衰竭（HF）的管理有了显著进展。本文旨在整合关于这些抑制剂在该患者群体中治疗HF疗效的现有知识。我们检索了包括PubMed、Scopus和Web of Science在内的主要医学数据库，重点关注过去十年的研究。本次综述的结果突出了SGLT2抑制剂的作用机制、临床益处、患者管理中的挑战以及使用这些抑制剂的相关结局。研究发现，这些药物不仅能改善血糖控制，还具有显著的心血管和肾脏益处，可降低心血管死亡率和主要不良心血管事件。然而，挑战和知识空白依然存在，尤其是在不同人群中的长期影响和安全性方面。本次综述的结论强调了更新临床指南以纳入这些研究结果的重要性，并提出需要开展未来研究以填补现有空白并优化SGLT2抑制剂在临床实践中的使用。
